3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Polycystic Ovary Syndrome
2
Uterine Anomalies
1
Salpingitis
1
Primary Ovarian Insufficiency
1
Pregnancy, Ectopic
1
Leiomyoma
1
Infertility, Female
1
Infertility
1
Endometritis
1
Endometriosis
1
Interventions
Metformin
91
Clomiphene
31
Letrozole
23
Inositol
19
Folic Acid
11
Chorionic Gonadotropin
11
Exercise
10
High-Intensity Interval Training
9
drospirenone and ethinyl estradiol combination
8
Ethinyl Estradiol
8
Contraceptives, Oral
8
Cholecalciferol
8
cetrorelix
7
Tablets
7
Progesterone
7
Menotropins
6
follitropin alfa
5
Pioglitazone
5
Liraglutide
5
Exenatide
5
Cyproterone Acetate
5
Caloric Restriction
5
Vitamin D
4
Triptorelin Pamoate
4
Surveys and Questionnaires
4
Sugars
4
Spironolactone
4
Glycoprotein Hormones, alpha Subunit
4
Fish Oils
4
Estradiol
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Polycystic Ovary Syndrome
×
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
×
Clear all
NCT04071574
2023-05-09
CS-EOSP-ICSI
Lebanese University
Phase 1/2
Completed
200 enrolled
NCT02607293
2018-06-28
ARTIST
Merck KGaA, Darmstadt, Germany
Completed
1,064 enrolled